Long-term observational study of sporadic inclusion body myositis
Top Cited Papers
Open Access
- 12 October 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 134 (11), 3176-3184
- https://doi.org/10.1093/brain/awr213
Abstract
We describe a long-term observational study of a large cohort of patients with sporadic inclusion body myositis and propose a sporadic inclusion body myositis weakness composite index that is easy to perform during a clinic. Data collection from two groups of patients (Paris and Oxford) was completed either during a clinic visit (52%), or by extraction from previous medical records (48%). One hundred and thirty-six patients [57% males, 61 (interquartile range 55–69) years at onset] were included. At the last visit all patients had muscle weakness (proximal British Medical Research Council scale P < 0.001) and Rivermead Mobility Index (correlation coefficient: 0.85; P < 0.001), decreased significantly with disease duration (correlation coefficient: −0.47; P < 0.001). The risk of death was only influenced by older age at onset of first symptoms. Seventy-one (52%) patients received immunosuppressive treatments [prednisone in 91.5%, associated (in 64.8%) with other immunomodulatory drugs (intravenous immunoglobulins, methotrexate or azathioprine) for a median duration of 40.8 months]. At the last assessment, patients who had been treated were more severely affected on disability scales (Walton P = 0.007, Rivermead Mobility Index P = 0.004) and on the sporadic inclusion body myositis weakness composite index (P = 0.04). The first stage of disease progression towards handicap for walking was more rapid among patients receiving immunosuppressive treatments (hazard ratio = 2.0, P = 0.002). This study confirms that sporadic inclusion body myositis is slowly progressive but not lethal and that immunosuppressive treatments do not ameliorate its natural course, thus confirming findings from smaller studies. Furthermore, our findings suggest that immunosuppressant drug therapy could have modestly exacerbated progression of disability. The sporadic inclusion body myositis weakness composite index might be a valuable outcome measure for future clinical trials, but requires further assessment and validation.This publication has 36 references indexed in Scilit:
- Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositisBrain, 2009
- Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approachesThe Lancet Neurology, 2007
- Shared blood and muscle CD8+ T-cell expansions in inclusion body myositisBrain, 2006
- Inclusion body myositisZeitschrift für Neurologie, 2005
- Anti–T-lymphocyte globulin treatment in inclusion body myositisNeurology, 2003
- Randomized pilot trial of βINF1a (Avonex) in patients with inclusion body myositisNeurology, 2001
- Inclusion body myositis and myopathiesAnnals of Neurology, 1995
- Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 casesActa Neurologica Scandinavica, 1994
- Inclusion body myositis : clinical and histopathological features of 36 patientsJournal of Molecular Medicine, 1993
- INCLUSION BODY MYOSITISBrain, 1989